A service of arranging or bringing about contact between an investment manager and an issuer or potential issuer.
Company to Provide Investor Update on November 19 at 4:30pm ET (Details Below)SARASOTA, Fla., Nov. 16, 2020 -- INVO Bioscience, Inc. (Nasdaq: INVO), a medical device company focused on creating alternative treatments for patients diagnosed with infertility and...
Joint Venture Targets the Large and Growing Mexico Market for Infertility ServicesSARASOTA, Fla., Sept. 30, 2020 -- INVO Bioscience, Inc. (OTCQB: INVO) developers of INVOcell®, the world's only in vivo Intravaginal Culture System, announced today it has teamed up...
INVO's Board strengthened with independent directors as we enter a new growth trajectory for the CompanySARASOTA, Fla., Sept. 16, 2020 -- INVO Bioscience, Inc. (OTCQB: INVO), a medical device company focused on creating alternative treatments for patients diagnosed...
Company to Provide Investor Update During Virtual Investor Conference on August 19 at 2:00pm ET (Details Below); Management Available for Virtual 1x1 MeetingsSARASOTA, Fla., Aug. 13, 2020 -- INVO Bioscience, Inc. (OTCQB: INVO), a medical device company focused on...
SARASOTA, Fla., Aug. 6, 2020 -- INVO Bioscience, Inc. (OTCQB: INVO), ("the Company", "INVO") a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell®, the world's only in vivo...
- An estimated 15% to 20% of the Turkish population suffers from the difficulty of conceiving- "As the world's only Intravaginal Culture System, INVOcell, a streamlined treatment solution, is uniquely positioned to address the challenges within the infertility...
- According to AIRM, "IVF with INVOcell is a simple, cost-effective, and highly rewarding methodology to increase access to care for assisted reproduction"- Industry forecasts suggest that only 1% to 2% of the estimated 150 million infertile couples worldwide are...
SARASOTA, Fla., June 29, 2020 -- INVO Bioscience, Inc. (OTCQB: INVO), a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell®, the world's only in vivo Intravaginal Culture System,...
SARASOTA, Fla., June 23, 2020 -- INVO Bioscience, Inc. (OTCQB: INVO), ("the Company") a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell®, the world's only in vivo Intravaginal...
Currently, it is estimated that only 1% to 2% of the estimated 150 million infertile couples worldwide are currently being treatedSARASOTA, Fla., June 19, 2020 -- Today, Steve Shum, Chief Executive Officer of INVO Bioscience, Inc. (OTCQB: INVO) (OTCQB: INVOD), a...